‘Nonsensical’ type 2 draft guidelines to be revisited
NICE has reopened the consultation on its new draft guidelines for type 2 diabetes in response to calls made from the diabetes community.
The first draft received widespread criticism from clinicians and was branded as “nonsensical” with too much emphasis on “cutting costs”. The health watchdog has set a deadline of 5pm on July 24 for further comments.
David Millar-Jones, Chair of the Primary Care Diabetes Society (PCDS), said the organisation had been “concerned” about the original draft version as it believed the content would be “subject to confusion and place patients at risk”.
He added: “We drafted a letter to NICE expressing our concerns. This was supported by other organisations who are leaders in clinical management. Despite little acknowledgement and several emails asking for review of the “substantive changes” that we were told had been made, we are delighted that this has now been put forward for a further consultation.”
The draft had also mentioned using repaglinide as an alternative first-line therapy for people who are intolerant to metformin. However, that was also criticised as the agent has been used very little since its launch in the 1990s and most clinicians are unfamiliar with it.
A NICE spokesperson said: “We encourage anyone with a relevant interest to submit their views via the NICE website so they can be fully considered by the guideline development group and help inform the final guideline.”